<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430076</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0205</org_study_id>
    <nct_id>NCT03430076</nct_id>
  </id_info>
  <brief_title>Polytetrafluoroethylen (PTFE) Vascular Prostheses With Heparin Bonded Luminal Surfaces vs Crude ePTFE</brief_title>
  <acronym>REPLACE</acronym>
  <official_title>Polytetrafluoroethylen (PTFE) Vascular Prostheses With Heparin Bonded Luminal Surfaces vs Crude ePTFE in the Treatment of Critical Limb Ischemia Lesions in the Absence of a Suitable Autologous Vein</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open repair could be recommended in a first line of treatment to revascularize critical limb
      ischemia patients or performed in a second line of treatment in case of failure of
      endovascular repair. A good quality vein is one of the main factors that influence the
      clinical success of open revascularization for below-knee popliteal. In the absence of an
      suitable autologous vein, prosthesis such as polytetrafluoroethylen (PTFE) graft could be an
      option but demonstrated worse clinical and morphological results compared to autologous
      greater saphenous vein. Consequently, there is still a room for improvement in CLI patients
      in the absence of an suitable autologous vein in whom endovascular repair failed.

      Recently, PTFE with heparin-bound to the luminal surface (Hb-PTFE) significantly reduced the
      overall risk of primary graft failure by 37%, in particular, risk reduction was 50% in
      femoropopliteal bypass cases in cases with critical ischemia (58% Primary patency for crude
      ePTFE versus 80% primary patency for PROPATEN at 1 year follow-up) (Lindholt, et. al. 2011).

      Additionally, a weighted average from the literature suggests a 76% primary patency for below
      knee bypasses performed with PROPATEN at one year follow-up, whereas a published
      meta-analysis suggests a 59% primary patency for below knee crude ePTFE at one year
      follow-up. At two year follow-up using the same approach, the average primary patency for
      PROPATEN was 67% versus 43% for standard ePTFE.

      The aim of this study is to assess PTFE with heparin-bound to the luminal surface as an
      alternative to crude PTFE in absence of good venous conduit in patients with CLI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient inclusion in this study will be proposed 60 to 1-days period preceding the surgical
      procedure. The patient will be randomized in the crude PTFE or in the Propaten groups.
      Regarding the intervention, the technique used during the therapeutic procedure shall be left
      to the operator's discretion, except the type of the graft. Demographic, intraoperative and
      postoperative data will be collected prospectively. Patient will be assessed and followed up
      according a current care. The cost difference between both groups will be identified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency at 1 year:</measure>
    <time_frame>1 year</time_frame>
    <description>It was defined as a patent graft without any intervention to open up or prevent a graft occlusion. Demonstrably patent graft should be by a duplex ultrasound color-flow scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success defined as a patent bypass without stenosis of the proximal and the distal anastomoses.</measure>
    <time_frame>2 years</time_frame>
    <description>Stenosis was defined as &gt;30% diameter stenosis noted on intraoperative arteriography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative complications</measure>
    <time_frame>2 years</time_frame>
    <description>defined as any general complications or local complications that caused or prolonged hospitalization and/or re-intervention, lymphorrhea of more than 3-days and post-operative paresthesia that required drugs. The general complications included death from any cause, MACE. Local complications included MALE, hematoma, active bleeding, local infection, thrombosis, delayed wound healing and false aneurysm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary sustained clinical improvement</measure>
    <time_frame>1, 12 and 24 months post procedure</time_frame>
    <description>defined as a wound healing and rest pain resolution for patients in CLI, without the need for repeated graft it self or anastomoses in surviving patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary sustained clinical improvement</measure>
    <time_frame>1, 12 and 24 months post procedure</time_frame>
    <description>defined as primary sustained clinical improvement including the need for repeated graft it self or anastomoses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>1 and 24 months post procedure</time_frame>
    <description>defined as a patent graft without any intervention to open up or prevent a graft occlusion. Demonstrably patent graft should be by a duplex ultrasound color-flow scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>1, 12 and 24 months post procedure</time_frame>
    <description>defined as MACEs including all cardiac deaths, Q wave infarction, stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MALE (Major Adverse Limb Event)-free survival rates in subjects with CLI randomized to Propaten vs. crude ePTFE.</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>MALE is defined as above-ankle amputation of the index limb or major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/ thrombolysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb salvage defined as freedom from above-ankle amputation of the index limb</measure>
    <time_frame>1, 12 and 24 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary patency</measure>
    <time_frame>1, 12 and 24 months post procedure</time_frame>
    <description>secondary patency in which graft patency is lost (occlusion) and restored by thrombectomy, thrombolysis, or transluminal angioplasty, and/or any problems with the graft itself or one of its anastomoses require revision or reconstruction. Demonstrably patent graft should be by a duplex ultrasound color-flow scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted patency</measure>
    <time_frame>1, 12 and 24 months post procedure</time_frame>
    <description>: Assisted patency at 1, 12 and 24 months post procedure, in which patency was never lost but maintained by prophylactic intervention. Demonstrably patent graft should be by a duplex ultrasound color-flow scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1, 12 and 24 months post procedure</time_frame>
    <description>Death (all cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index</measure>
    <time_frame>1, 6, 12 and 24 months post procedure</time_frame>
    <description>Post-operative assessment (clinical, morphological, hemodynamic criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at inclusion, .</measure>
    <time_frame>1, 3, 6, 9, 12, 15, 18 and 24 months</time_frame>
    <description>assessed according the EQ-5D-3L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost utility analysis (CUA)</measure>
    <time_frame>2 years</time_frame>
    <description>In CUA, the outcomes of an intervention are evaluated in terms of Quality-Adjusted Life-Years (QALYs). QALYs are a numerical index that encompasses both the length of life and the health-related quality-of-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness analysis (CEA)</measure>
    <time_frame>2 years</time_frame>
    <description>The Measure of outcome for CEA will be the number of Life Years Gained (LYG) at 2 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Ischemia Lesions</condition>
  <arm_group>
    <arm_group_label>Revascularization by (Propaten)®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revascularization by PTFE with heparin bonded luminal surface (Propaten)®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revascularization by Crude PTFE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>revascularization</intervention_name>
    <description>open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.</description>
    <arm_group_label>Revascularization by (Propaten)®</arm_group_label>
    <arm_group_label>Revascularization by Crude PTFE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Propaten®</intervention_name>
    <description>Propaten®</description>
    <arm_group_label>Revascularization by (Propaten)®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crude PTFE</intervention_name>
    <description>Crude PTFE</description>
    <arm_group_label>Revascularization by Crude PTFE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient ≥18 years

          -  Patient presented critical limb ischemia (Rutherford classification: 4-6)

          -  Indication of below the knee bypass with an artificial graft

          -  Absence of an suitable autologous vein

          -  Patient is affiliated to the Social Security or equivalent system

          -  Patient has been informed of the nature of the study, agrees to its provisions and has
             signed the informed consent form prior to any study related procedure

          -  Patient agrees to undergo all protocol required follow-up examinations and
             requirements at the investigational site

        Exclusion Criteria:

          -  No atheromatous disease

          -  Female of child bearing potential

          -  Patient has a history of coagulopathy or will refuse blood transfusions

          -  Patient is receiving or scheduled to receive anticancer therapy for malignancy within
             1 year prior to or after the procedure

          -  Severe concomitant disease with life expectation &lt; one year

          -  Known allergy to heparin

          -  Indication for ipsilateral major amputation

          -  Patient is not able to give informed consent

          -  Patient is currently participating in an investigational drug or device study that has
             not completed the primary endpoint or that clinically interferes with the current
             study endpoints Note: Trials requiring extended follow-up for products that were
             investigational, but have become commercially suitable since then, are not considered
             investigational trials

          -  In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit
             the patient's ability to participate in the study, compliance with follow-up
             requirements or impact the scientific integrity of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yann Gouëffic, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yann Gouëffic, Pr</last_name>
    <phone>2 40 16 50 93</phone>
    <phone_ext>+ 33</phone_ext>
    <email>yann.goueffic@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49 933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Picquet, Pr</last_name>
      <phone>02 41 35 38 37</phone>
      <phone_ext>+33</phone_ext>
      <email>jean.picquet@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Besançon University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>simon Rickenbach, Pr</last_name>
      <phone>03 81 66 81 19</phone>
      <phone_ext>+33</phone_ext>
      <email>srinckenbach@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Ducasse, Pr</last_name>
      <phone>05 56 79 55 26</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.ducasse@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ambroise Paré university Hospital</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphaël Coscas, Dr</last_name>
      <phone>06 63 49 56 36</phone>
      <phone_ext>+33</phone_ext>
      <email>raphael.coscas@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63 003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugénio Rosset, Pr</last_name>
      <phone>4 73 75 15 12</phone>
      <phone_ext>+33</phone_ext>
      <email>erosset@chuclermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijon University Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Steinmetz, Pr</last_name>
      <phone>3 80 29 33 52</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.steinmetz@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Sobocinski, Dr</last_name>
      <phone>03 20 44 58 11</phone>
      <phone_ext>+33</phone_ext>
      <email>jonathan.sobocinski@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon University Hospital - Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Feugier, Pr</last_name>
      <phone>04 72 11 78 07</phone>
      <phone_ext>+33</phone_ext>
      <email>patrick.feugier@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Timone hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Bartoli, Dr</last_name>
      <phone>04 91 38 57 62</phone>
      <phone_ext>+33</phone_ext>
      <email>michel.bartoli@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicla Settembre, Dr</last_name>
      <phone>03 83 15 43 84</phone>
      <phone_ext>+33</phone_ext>
      <email>N.SETTEMBRE@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Gouëffic, Pr</last_name>
      <phone>02 40 16 50 93</phone>
      <phone_ext>+33</phone_ext>
      <email>yann.goueffic@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eva Le Pogam</last_name>
      <email>eva.lepogam@chu-nantes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Réda Hassen Khodja, Pr</last_name>
      <phone>04 92 03 38 35</phone>
      <phone_ext>+33</phone_ext>
      <email>hassen-khodja.r@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Julia, Pr</last_name>
      <phone>1 56 09 30 91</phone>
      <phone_ext>+33</phone_ext>
      <email>pierre.julia@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Castier Yves-Hervé, Pr</last_name>
      <phone>01 40 25 69 62</phone>
      <phone_ext>+33</phone_ext>
      <email>yves.castier@bch.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Schneider Fabrice, Dr</last_name>
      <phone>5 49 44 36 32</phone>
      <phone_ext>+33</phone_ext>
      <email>fabrice.schneider@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reims university Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amboise Duprey, Dr</last_name>
      <email>ambroise.duprey@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrien Kaladji, Dr</last_name>
      <email>adrien.kaladji@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Etienne University Hospital</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Favre Jean-Pierre, Pr</last_name>
      <phone>04 77 82 83 81</phone>
      <email>j.pierre.favre@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabien Thaveau, Pr</last_name>
      <phone>0369550927</phone>
      <phone_ext>+33</phone_ext>
      <email>fabien.thaveau@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valenciennes University Hospital</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélia Bianchini, Dr</last_name>
      <phone>03 27 14 33 33</phone>
      <phone_ext>+33</phone_ext>
      <email>bianchini-a@ch-valenciennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vascular prostheses</keyword>
  <keyword>heparin</keyword>
  <keyword>ischemia lesions</keyword>
  <keyword>vascular</keyword>
  <keyword>critical limb ischemia lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

